144 related articles for article (PubMed ID: 19783139)
1. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected].
Sato T; Ashizawa N; Matsumoto K; Iwanaga T; Nakamura H; Inoue T; Nagata O
Bioorg Med Chem Lett; 2009 Nov; 19(21):6225-9. PubMed ID: 19783139
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and pharmacological and pharmacokinetic evaluation of 3-phenyl-5-pyridyl-1,2,4-triazole derivatives as xanthine oxidoreductase inhibitors.
Sato T; Ashizawa N; Iwanaga T; Nakamura H; Matsumoto K; Inoue T; Nagata O
Bioorg Med Chem Lett; 2009 Jan; 19(1):184-7. PubMed ID: 19027292
[TBL] [Abstract][Full Text] [Related]
3. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase.
Matsumoto K; Okamoto K; Ashizawa N; Nishino T
J Pharmacol Exp Ther; 2011 Jan; 336(1):95-103. PubMed ID: 20952484
[TBL] [Abstract][Full Text] [Related]
4. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051.
Okamoto K; Nishino T
J Nippon Med Sch; 2008 Feb; 75(1):2-3. PubMed ID: 18360072
[TBL] [Abstract][Full Text] [Related]
5. [Inhibitors of xanthine oxidoreductase].
Okamoto K
Nihon Rinsho; 2008 Apr; 66(4):748-53. PubMed ID: 18409526
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and bioevaluation of 1-phenyl-pyrazole-4-carboxylic acid derivatives as potent xanthine oxidoreductase inhibitors.
Li J; Wu F; Liu X; Zou Y; Chen H; Li Z; Zhang L
Eur J Med Chem; 2017 Nov; 140():20-30. PubMed ID: 28918097
[TBL] [Abstract][Full Text] [Related]
7. Metabolic profile of FYX-051 (4-(5-pyridin-4-yl-1h-[1,2,4]triazol-3-yl)pyridine-2-carbonitrile) in the rat, dog, monkey, and human: identification of N-glucuronides and N-glucosides.
Nakazawa T; Miyata K; Omura K; Iwanaga T; Nagata O
Drug Metab Dispos; 2006 Nov; 34(11):1880-6. PubMed ID: 16914512
[TBL] [Abstract][Full Text] [Related]
8. Study on species differences in nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor.
Shimo T; Ashizawa N; Moto M; Iwanaga T; Nagata O
Arch Toxicol; 2011 May; 85(5):505-12. PubMed ID: 20936465
[TBL] [Abstract][Full Text] [Related]
9. The effects of topiroxostat on vascular function in patients with hyperuricemia.
Higa S; Shima D; Tomitani N; Fujimoto Y; Kario K
J Clin Hypertens (Greenwich); 2019 Nov; 21(11):1713-1720. PubMed ID: 31556223
[TBL] [Abstract][Full Text] [Related]
10. Characterization of N-glucuronidation of 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): a new xanthine oxidoreductase inhibitor.
Omura K; Nakazawa T; Sato T; Iwanaga T; Nagata O
Drug Metab Dispos; 2007 Dec; 35(12):2143-8. PubMed ID: 17761779
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and bioevaluation of 1-phenylimidazole-4-carboxylic acid derivatives as novel xanthine oxidoreductase inhibitors.
Zhou H; Li X; Li Y; Zhu X; Zhang L; Li J
Eur J Med Chem; 2020 Jan; 186():111883. PubMed ID: 31761385
[TBL] [Abstract][Full Text] [Related]
12. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
Nakamura T; Murase T; Nampei M; Morimoto N; Ashizawa N; Iwanaga T; Sakamoto R
Eur J Pharmacol; 2016 Jun; 780():224-31. PubMed ID: 27038523
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of 5-(4-(pyridin-4-yl)-1H-1,2,3-triazol-1-yl)benzonitrile derivatives as xanthine oxidase inhibitors.
Zhang TJ; Li SY; Zhang Y; Wu QX; Meng FH
Chem Biol Drug Des; 2018 Feb; 91(2):526-533. PubMed ID: 28950055
[TBL] [Abstract][Full Text] [Related]
14. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Chen C; Lü JM; Yao Q
Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
[TBL] [Abstract][Full Text] [Related]
15. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).
Wada T; Hosoya T; Honda D; Sakamoto R; Narita K; Sasaki T; Okui D; Kimura K
Clin Exp Nephrol; 2018 Aug; 22(4):860-870. PubMed ID: 29372470
[TBL] [Abstract][Full Text] [Related]
16. FYX-051, a xanthine oxidoreductase inhibitor, induces nephropathy in rats, but not in monkeys.
Shimo T; Ashizawa N; Moto M; Matsumoto K; Iwanaga T; Nagata O
Toxicol Pathol; 2009 Jun; 37(4):438-45. PubMed ID: 19336671
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel 1,2,4-triazole derivatives as xanthine oxidoreductase inhibitors with hypouricemic effects.
Yang Y; Yan D; Cheng H; Nan G; Hou X; Ren L; Yang Y; Li X; Tian J; Ye F; Xiao Z
Bioorg Chem; 2022 Dec; 129():106162. PubMed ID: 36183564
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous treatment with citrate prevents nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.
Shimo T; Ashizawa N; Matsumoto K; Nakazawa T; Nagata O
Toxicol Sci; 2005 Sep; 87(1):267-76. PubMed ID: 15933230
[TBL] [Abstract][Full Text] [Related]
19. Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion.
Terawaki H; Hoshi H; Kazama JJ
Clin Exp Nephrol; 2017 Apr; 21(2):356-357. PubMed ID: 28247173
[No Abstract] [Full Text] [Related]
20. Strain differences in the responsiveness between Sprague-Dawley and Fischer rats to nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor.
Ashizawa N; Shimo T; Matsumoto K; Oba K; Nakazawa T; Nagata O
Toxicol Appl Pharmacol; 2006 Dec; 217(3):260-5. PubMed ID: 17084874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
